Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India.
<h4>Background</h4>Significant adverse events (AE) have been reported in patients receiving medications for multidrug- and extensively-drug-resistant tuberculosis (MDR-TB & XDR-TB). However, there is little prospective data on AE in MDR- or XDR-TB/HIV co-infected patients on antitube...
Guardado en:
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2012
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/c28ca6ce02fc445699a1401218f8fcff |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:c28ca6ce02fc445699a1401218f8fcff |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:c28ca6ce02fc445699a1401218f8fcff2021-11-18T07:12:50ZAdverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India.1932-620310.1371/journal.pone.0040781https://doaj.org/article/c28ca6ce02fc445699a1401218f8fcff2012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22792406/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Significant adverse events (AE) have been reported in patients receiving medications for multidrug- and extensively-drug-resistant tuberculosis (MDR-TB & XDR-TB). However, there is little prospective data on AE in MDR- or XDR-TB/HIV co-infected patients on antituberculosis and antiretroviral therapy (ART) in programmatic settings.<h4>Methods</h4>Médecins Sans Frontières (MSF) is supporting a community-based treatment program for drug-resistant tuberculosis in HIV-infected patients in a slum setting in Mumbai, India since 2007. Patients are being treated for both diseases and the management of AE is done on an outpatient basis whenever possible. Prospective data were analysed to determine the occurrence and nature of AE.<h4>Results</h4>Between May 2007 and September 2011, 67 HIV/MDR-TB co-infected patients were being treated with anti-TB treatment and ART; 43.3% were female, median age was 35.5 years (Interquartile Range: 30.5-42) and the median duration of anti-TB treatment was 10 months (range 0.5-30). Overall, AE were common in this cohort: 71%, 63% and 40% of patients experienced one or more mild, moderate or severe AE, respectively. However, they were rarely life-threatening or debilitating. AE occurring most frequently included gastrointestinal symptoms (45% of patients), peripheral neuropathy (38%), hypothyroidism (32%), psychiatric symptoms (29%) and hypokalaemia (23%). Eleven patients were hospitalized for AE and one or more suspect drugs had to be permanently discontinued in 27 (40%). No AE led to indefinite suspension of an entire MDR-TB or ART regimen.<h4>Conclusions</h4>AE occurred frequently in this Mumbai HIV/MDR-TB cohort but not more frequently than in non-HIV patients on similar anti-TB treatment. Most AE can be successfully managed on an outpatient basis through a community-based treatment program, even in a resource-limited setting. Concerns about severe AE in the management of co-infected patients are justified, however, they should not cause delays in the urgently needed rapid scale-up of antiretroviral therapy and second-line anti-TB treatment.Petros IsaakidisBhanumati VargheseHoma MansoorHelen S CoxJoanna LadomirskaPeter SaranchukEsdras Da SilvaSamsuddin KhanRoma ParyaniZarir UdwadiaGiovanni Battista MiglioriGiovanni SotgiuTony ReidPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 7, p e40781 (2012) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Petros Isaakidis Bhanumati Varghese Homa Mansoor Helen S Cox Joanna Ladomirska Peter Saranchuk Esdras Da Silva Samsuddin Khan Roma Paryani Zarir Udwadia Giovanni Battista Migliori Giovanni Sotgiu Tony Reid Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India. |
| description |
<h4>Background</h4>Significant adverse events (AE) have been reported in patients receiving medications for multidrug- and extensively-drug-resistant tuberculosis (MDR-TB & XDR-TB). However, there is little prospective data on AE in MDR- or XDR-TB/HIV co-infected patients on antituberculosis and antiretroviral therapy (ART) in programmatic settings.<h4>Methods</h4>Médecins Sans Frontières (MSF) is supporting a community-based treatment program for drug-resistant tuberculosis in HIV-infected patients in a slum setting in Mumbai, India since 2007. Patients are being treated for both diseases and the management of AE is done on an outpatient basis whenever possible. Prospective data were analysed to determine the occurrence and nature of AE.<h4>Results</h4>Between May 2007 and September 2011, 67 HIV/MDR-TB co-infected patients were being treated with anti-TB treatment and ART; 43.3% were female, median age was 35.5 years (Interquartile Range: 30.5-42) and the median duration of anti-TB treatment was 10 months (range 0.5-30). Overall, AE were common in this cohort: 71%, 63% and 40% of patients experienced one or more mild, moderate or severe AE, respectively. However, they were rarely life-threatening or debilitating. AE occurring most frequently included gastrointestinal symptoms (45% of patients), peripheral neuropathy (38%), hypothyroidism (32%), psychiatric symptoms (29%) and hypokalaemia (23%). Eleven patients were hospitalized for AE and one or more suspect drugs had to be permanently discontinued in 27 (40%). No AE led to indefinite suspension of an entire MDR-TB or ART regimen.<h4>Conclusions</h4>AE occurred frequently in this Mumbai HIV/MDR-TB cohort but not more frequently than in non-HIV patients on similar anti-TB treatment. Most AE can be successfully managed on an outpatient basis through a community-based treatment program, even in a resource-limited setting. Concerns about severe AE in the management of co-infected patients are justified, however, they should not cause delays in the urgently needed rapid scale-up of antiretroviral therapy and second-line anti-TB treatment. |
| format |
article |
| author |
Petros Isaakidis Bhanumati Varghese Homa Mansoor Helen S Cox Joanna Ladomirska Peter Saranchuk Esdras Da Silva Samsuddin Khan Roma Paryani Zarir Udwadia Giovanni Battista Migliori Giovanni Sotgiu Tony Reid |
| author_facet |
Petros Isaakidis Bhanumati Varghese Homa Mansoor Helen S Cox Joanna Ladomirska Peter Saranchuk Esdras Da Silva Samsuddin Khan Roma Paryani Zarir Udwadia Giovanni Battista Migliori Giovanni Sotgiu Tony Reid |
| author_sort |
Petros Isaakidis |
| title |
Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India. |
| title_short |
Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India. |
| title_full |
Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India. |
| title_fullStr |
Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India. |
| title_full_unstemmed |
Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India. |
| title_sort |
adverse events among hiv/mdr-tb co-infected patients receiving antiretroviral and second line anti-tb treatment in mumbai, india. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2012 |
| url |
https://doaj.org/article/c28ca6ce02fc445699a1401218f8fcff |
| work_keys_str_mv |
AT petrosisaakidis adverseeventsamonghivmdrtbcoinfectedpatientsreceivingantiretroviralandsecondlineantitbtreatmentinmumbaiindia AT bhanumativarghese adverseeventsamonghivmdrtbcoinfectedpatientsreceivingantiretroviralandsecondlineantitbtreatmentinmumbaiindia AT homamansoor adverseeventsamonghivmdrtbcoinfectedpatientsreceivingantiretroviralandsecondlineantitbtreatmentinmumbaiindia AT helenscox adverseeventsamonghivmdrtbcoinfectedpatientsreceivingantiretroviralandsecondlineantitbtreatmentinmumbaiindia AT joannaladomirska adverseeventsamonghivmdrtbcoinfectedpatientsreceivingantiretroviralandsecondlineantitbtreatmentinmumbaiindia AT petersaranchuk adverseeventsamonghivmdrtbcoinfectedpatientsreceivingantiretroviralandsecondlineantitbtreatmentinmumbaiindia AT esdrasdasilva adverseeventsamonghivmdrtbcoinfectedpatientsreceivingantiretroviralandsecondlineantitbtreatmentinmumbaiindia AT samsuddinkhan adverseeventsamonghivmdrtbcoinfectedpatientsreceivingantiretroviralandsecondlineantitbtreatmentinmumbaiindia AT romaparyani adverseeventsamonghivmdrtbcoinfectedpatientsreceivingantiretroviralandsecondlineantitbtreatmentinmumbaiindia AT zarirudwadia adverseeventsamonghivmdrtbcoinfectedpatientsreceivingantiretroviralandsecondlineantitbtreatmentinmumbaiindia AT giovannibattistamigliori adverseeventsamonghivmdrtbcoinfectedpatientsreceivingantiretroviralandsecondlineantitbtreatmentinmumbaiindia AT giovannisotgiu adverseeventsamonghivmdrtbcoinfectedpatientsreceivingantiretroviralandsecondlineantitbtreatmentinmumbaiindia AT tonyreid adverseeventsamonghivmdrtbcoinfectedpatientsreceivingantiretroviralandsecondlineantitbtreatmentinmumbaiindia |
| _version_ |
1718423814596984832 |